FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex

FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex

Source: 
Fierce Biotech
snippet: 

The FDA has accepted Sanofi’s filing for approval of its Darzalex rival in relapsed/refractory multiple myeloma. Sanofi will learn whether the FDA will approve anti-CD38 antibody isatuximab by the end of April 2020.